Eli Lilly said Monday that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity, according to results from a late-stage trial. The company plans to file for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity or who are overweight by the end of the year.
Obstructive sleep apnea refers to interrupted breathing during sleep caused by narrowed or blocked airways. The condition can lead to drops in oxygen and increases in blood pressure, which the report links to serious complications such as hypertension, heart failure and stroke. The report says nearly 1 billion adults worldwide have the condition, including 80 million people ages 20 and over in the U.S., citing the National Council on Aging. Lilly said most cases have never been diagnosed.
The trial included two studies. The first enrolled 363 patients who were unable or unwilling to use positive airway pressure (PAP) therapy. The second enrolled 349 people who had used PAP therapy for at least three months and continued it during the trial.
In the first group, patients taking Foundayo had an average of 21.1 fewer apnea-hypopnea index (AHI) events per hour at 52 weeks, compared with 4.8 fewer for those on placebo. Lilly said 31.5% of the Foundayo group met criteria for remission or improvement to mild OSA.
In the second group, patients taking Foundayo with PAP therapy had an average of 18.3 fewer AHI events per hour at 52 weeks, compared with 5.5 fewer on placebo. Lilly said 19.6% of this group met criteria for remission or mild OSA.
Lilly said the pill also helped patients lose about 11% of their weight across groups at 52 weeks. About 12% of patients not using PAP therapy stopped taking Foundayo because of side effects, compared with 3.8% on placebo. The most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, which the report describes as generally mild to moderate.